Literature DB >> 30802612

A Chinese medicine formula (Jinqi Jiangtang Tablet): A review on its chemical constituents, quality control, pharmacokinetics studies, pharmacological properties and clinical applications.

Yi Liu1, Aiting Wang2, Lina Wen2, Zhirui Yang2, Xinyu Yang2, Xu Zhang3, Dan Yan4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Diabetes belongs to the category of "Xiao Ke Zheng" in the field of traditional Chinese medicine (TCM) and has been listed as one of the predominant diseases of TCM. Jinqi Jiangtang Tablet (JQJTT), a Chinese medicine formula composed of three herbs (Coptis chinensis, Astragalus membranaceus and Lonicera japonica), is an effective prescription for diabetes proved by randomized, double-blind, placebo-controlled trials. AIM OF THE REVIEW: To analyze systematic and up-to-date classification information on the study of JQJTT, explain the problems existing in the current research of classics formulas, and further propose the solution, providing a reference for future study.
MATERIALS AND METHODS: Literatures on JQJTT were collected from a variety of databases, including PubMed, Google Scholar, Science Direct, Wiley, Web of Science, China National Knowledge Infrastructure, and WanFang Data. Information was also collected from books and reports, such as Chinese Pharmacopoeia, Chinese herbal classic books and reports of re-evaluation on post-marketing drugs conducted by companies.
RESULTS: There are some problems for JQJTT: the quality control system is not perfect, the pharmacological functional mechanism is not fully explained, and clinical applications need to be reevaluated. A few of research directions for future research are proposed: (i) the chemical quality evaluation combined with bioassay to evaluate quality; (ii) interaction based on gut microbiota in vivo; (iii) the effects of interaction between components of the polypharmacy on pharmacokinetic studies; (iv) interaction mechanism between drugs and endogenous small molecules and biomacromolecules; (v) evidence-based medicine reconfirmation for clinical evaluation.
CONCLUSIONS: The recent research status of JQJTT was summarized and analyzed from the aspects of chemical constituents, quality control, pharmacokinetics studies, pharmacological properties and clinical applications. This review takes JQJTT as an example, points out some typical problems and opinions about the TCM formulas, highlights the importance of the secondary development of classical formula, and lays a foundation for the further research.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical applications; Diabetes; Jinqi Jiangtang Tablet (JQJTT); Pharmacology; Quality control; Traditional Chinese medicine (TCM)

Mesh:

Substances:

Year:  2019        PMID: 30802612     DOI: 10.1016/j.jep.2019.02.038

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Refined-JinQi-JiangTang tablet ameliorates hypertension through activation of FGF21/FGFR1 axis in fructose-fed rats.

Authors:  Siming Li; Xiaoling Li; Jing Fan; Xinhang Jia; Hemeng Wang; Fangxin Dong; Haoyang Mao; Chen Zhang; Wenfei Wang; Ye Jiang; Lijun Yan; Na Zhang
Journal:  J Nat Med       Date:  2022-05-09       Impact factor: 3.192

2.  The Hypoglycemic Effect of JinQi Jiangtang Tablets Is Partially Dependent on the Palmatine-Induced Activation of the Fibroblast Growth Factor Receptor 1 Signaling Pathway.

Authors:  Siming Li; Xiaoling Li; HeMeng Wang; Xinhang Jia; Haoyang Mao; Fangxin Dong; Tingting Zhao; Yuan Gao; Chen Zhang; Ruisong Bai; Ruihao Liu; Lijun Yan; Yubin Ji; Na Zhang; Wenfei Wang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

3.  An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies.

Authors:  Min-Han Chi; Jung Chao; Chien-Yu Ko; Shyh-Shyun Huang
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

4.  Comparative efficacy and safety of traditional Chinese patent medicine for the treatment of type 2 diabetes mellitus: A Bayesian network meta-analysis protocol.

Authors:  Jie Li; Sen Zhao; Yanqin Huang; Chuancheng Li; Bing Li; Yunsheng Xu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.